Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Medibio Announces ISO 13485 Certification

Medibio Limited
Posted on: 10 Jan 18

SYDNEY, Australia and MINNEAPOLIS, Jan. 10, 2018 (GLOBE NEWSWIRE) --  Medibio Limited  ( MEB  or the  Company ) (ASX:MEB) (OTCQB:MDBIF) has received a Certificate of Compliance certifying that the Company's Quality Management System complies with the requirements of ISO 13485.  This also includes conformance with the Canadian Medical Device Conformity Assessment System (CMDCAS). 

The certification was issued by DQS Med, the Notified Body appointed to assess Medibio's submission for CE Mark. It signifies that Medibio has established a comprehensive quality system for the design and manufacturing of medical devices.  ISO 13485 is recognized internationally as a universal measure of quality and is a critical prerequisite to securing CE Mark and other regulatory certifications.

"This is an major milestone for the Company," said Medibio's CEO & Managing Director, Mr. Jack Cosentino.  "This accomplishment reflects the work of all individuals within the organization who all believe that this achievement of ISO certification echoes Medibio's commitment to the highest level of quality management and to operational and production excellence."

Following receipt of ISO certification, Medibio reaffirms its expectation of gaining CE Mark shortly.   

About Medibio Limited
Medibio (ASX:MEB) (OTCQB:MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:    Website: www.medibio.com.au
Medibio Shareholder Enquiries:
Investor Relations
Medibio Limited
info@medibio.com.au
T: +1 (952) 222-0551

Australian Media Enquiries:
Peter Taylor
NWR Communications
peter@nwrcommunications.com.au
T: +61 (0) 412 036 231



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Medibio Limited via GlobeNewswire
HUG#2160469
GlobeNewswire
globenewswire.com

Last updated on: 11/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.